Download MendeleyScaffold modifications to the 4-(4,4-dimethylpiperidinyl) 2,6-dimethylpyridinyl class of HIV-1 allosteric integrase inhibitors.
Parcella, K., Patel, M., Tu, Y., Eastman, K., Peese, K., Gillis, E., Belema, M., Dicker, I.B., McAuliffe, B., Ding, B., Falk, P., Simmermacher, J., Parker, D.D., Sivaprakasam, P., Khan, J.A., Kish, K., Lewis, H., Hanumegowda, U., Jenkins, S., Kadow, J.F., Krystal, M., Meanwell, N.A., Naidu, B.N.(2022) Bioorg Med Chem 67: 116833-116833
- PubMed: 35605346
- DOI: https://doi.org/10.1016/j.bmc.2022.116833
- Primary Citation of Related Structures:
7U2U - PubMed Abstract:
Allosteric integrase inhibitors (ALLINIs) of HIV-1 may hold promise as a novel mechanism for HIV therapeutics and cure. Scaffold modifications to the 4-(4,4-dimethylpiperidinyl) 2,6-dimethylpyridinyl class of ALLINIs provided a series of potent compounds with differentiated 5/6 fused ring systems. Notably, inhibitors containing the 1,2,4-triazolopyridine and imidazopyridine core exhibited single digit nM antiviral potency and low to moderate clearance after intravenous (IV) dosing in rat pharmacokinetic (PK) studies. The 1,2,4-triazolopyridines showed a higher oral exposure when compared to the imidazopyridines. Further modifications to the C5 substituent of the 1,2,4-triazolopyridines resulted in a new lead compound, which had improved rat IV/PO PK compared to the former lead compound GSK3739936, while maintaining antiviral potency. Structure-activity relationships (SAR) and rat pharmacokinetic profiles of this series are discussed.
Organizational Affiliation:
ViiV Healthcare, 36 East Industrial Road, Branford, CT 06405, USA. Electronic address: kyle.e.parcella@viivhealthcare.com.
